|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.30 SEK | +0.42% |
|
-8.31% | -14.60% |
| 06-23 | Citadel Back as Public Short Seller in Synact Pharma | FW |
| 06-18 | Edison Maintains Its Valuation for Synact Pharma After Trial Results | FW |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 106M | - | - | - | - | - |
| 1,070B | |||||
| 624B | |||||
| 450B | |||||
| 328B | |||||
| 284B |
- Stock Market
- Stocks
- SYNACT Stock
- Charts SynAct Pharma AB
- Sector Chart
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
